Bladder cancer (BC) is one of the most prevalent malignancies in men. Understanding
molecular characteristics via studying signaling pathways has made tremendous …

Introduction: Urothelial cancers (UC) include tumors of the bladder, upper tract, and proximal
urethra. Bladder cancer (BC) arises from urothelial cells lining the bladder and accounts for …

Bladder cancer is the ninth most frequently diagnosed cancer world-wide and ranks 13th in
cancer-related deaths. Two tremendous breakthroughs in bladder cancer therapy over the …

The treatment landscape for bladder cancer has undergone a rapid evolution in the past five
years with the approval of seven new agents. New classes of medications have improved …

The prognosis of advanced urothelial bladder cancer (UBC) is dismal despite conventional
platinum-based chemotherapy and, as such, new therapeutic agents are urgently needed …

The fact that there are now five immune checkpoint inhibitor (ICI) monoclonal antibodies
approved since 2016 that target programmed cell death protein 1 or programmed death …

Recent advances in molecular biology and drug design have described novel targets in
bladder cancer. EGFR, fibroblast growth factor receptor (FGFR), VEGFR, phosphoinositide 3 …

Bladder cancer is the fourth most common cancer worldwide and the eighth leading cause
of cancer mortality in men. The advent of new systemic therapies, including PD-1 and PD-L1 …

Simple Summary Bladder cancer accounts for a significant burden to global public health.
Despite advances in therapeutics with the advent of immunotherapy, only a small subset of …

Background: In advanced bladder cancer (BCa), platinum-based chemotherapy represents
the first-choice treatment. In the last ten years, immune checkpoint inhibitors (ICIs) have …